You are viewing the site in preview mode

Skip to main content

Advertisement

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Article metrics

  • 426 Accesses

The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:101

Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:101

Doi 10.1186/s40425-018-0421-z

Following publication of the original article [1], the authors reported an error in their listed affiliations.

In this Correction Dr. Jiaxin Zhao is related to two affiliations:

1. The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China.

3. The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.

The published apologizes for any inconvenience caused by this error.

Reference

  1. 1.

    Zhao, et al. Journal for ImmunoTherapy of Cancer. 2018;6(101). https://doi.org/10.1186/s40425-018-0421-z.

Download references

Author information

Correspondence to Bin Zhao or Hong Zhao or Jiaxin Zhao.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark